COTL1

Summary

COTL1 (coactosin like F-actin binding protein 1, HGNC:18304) is a protein-coding gene on chromosome 16q24.1, encoding Coactosin-like protein (Q14019). Binds to F-actin in a calcium-independent manner.

This gene encodes one of the numerous actin-binding proteins which regulate the actin cytoskeleton. This protein binds F-actin, and also interacts with 5-lipoxygenase, which is the first committed enzyme in leukotriene biosynthesis. Although this gene has been reported to map to chromosome 17 in the Smith-Magenis syndrome region, the best alignments for this gene are to chromosome 16. The Smith-Magenis syndrome region is the site of two related pseudogenes.

Source: NCBI Gene 23406 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 44 total
• MANE Select transcript: NM_021149

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:18304
Approved symbol	COTL1
Name	coactosin like F-actin binding protein 1
Location	16q24.1
Locus type	gene with protein product
Status	Approved
Aliases	CLP
Ensembl gene	ENSG00000103187
Ensembl biotype	protein_coding
OMIM	606748
Entrez	23406

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 3 protein_coding, 2 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000262428, ENST00000561707, ENST00000564057, ENST00000564662, ENST00000567278, ENST00000567786

RefSeq mRNA: 1 — MANE Select: NM_021149 NM_021149

CCDS: CCDS10947

Canonical transcript exons

ENST00000262428 — 4 exons

Exon	Start	End
ENSE00000945794	84617501	84617583
ENSE00001236259	84617838	84618078
ENSE00001325288	84565596	84566955
ENSE00003507433	84590105	84590262

Expression profiles

Bgee: expression breadth ubiquitous, 283 present calls, max score 99.65.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 211.5585 / max 2828.5509, expressed in 1822 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
158365	186.1083	1822
158364	23.8797	1762
158360	0.7695	408
158363	0.4763	234
158359	0.3247	176

Top tissues by expression

292 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
monocyte	CL:0000576	99.65	gold quality
leukocyte	CL:0000738	99.63	gold quality
granulocyte	CL:0000094	99.62	gold quality
mononuclear cell	CL:0000842	99.62	gold quality
blood	UBERON:0000178	99.49	gold quality
spleen	UBERON:0002106	99.09	gold quality
vermiform appendix	UBERON:0001154	98.93	gold quality
lymph node	UBERON:0000029	98.86	gold quality
cortical plate	UBERON:0005343	98.36	gold quality
caecum	UBERON:0001153	98.10	gold quality
pigmented layer of retina	UBERON:0001782	97.56	gold quality
retina	UBERON:0000966	97.53	gold quality
ganglionic eminence	UBERON:0004023	97.36	gold quality
embryo	UBERON:0000922	97.15	gold quality
bone marrow	UBERON:0002371	97.04	gold quality
gall bladder	UBERON:0002110	97.03	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	96.86	gold quality
right lung	UBERON:0002167	96.85	gold quality
body of stomach	UBERON:0001161	96.83	gold quality
pylorus	UBERON:0001166	96.78	gold quality
cranial nerve II	UBERON:0000941	96.74	gold quality
bone marrow cell	CL:0002092	96.72	gold quality
stromal cell of endometrium	CL:0002255	96.68	gold quality
spinal cord	UBERON:0002240	96.63	gold quality
pericardium	UBERON:0002407	96.34	gold quality
upper lobe of left lung	UBERON:0008952	96.29	gold quality
decidua	UBERON:0002450	96.15	gold quality
nephron tubule	UBERON:0001231	96.09	gold quality
bone element	UBERON:0001474	96.04	gold quality
upper lobe of lung	UBERON:0008948	96.04	gold quality

Single-cell (SCXA)

Detected in 50 experiment(s), a significant marker in 41.

Experiment	Marker?	Max mean expression
E-MTAB-6678	yes	8293.41
E-MTAB-6701	yes	5633.52
E-GEOD-149689	yes	4069.72
E-CURD-55	yes	3727.49
E-MTAB-10287	yes	2955.18
E-GEOD-139324	yes	2915.01
E-CURD-122	yes	2870.51
E-HCAD-24	yes	2814.38
E-MTAB-10553	yes	2374.60
E-GEOD-106540	yes	2215.50
E-MTAB-8911	yes	1986.45
E-HCAD-15	yes	1940.59
E-MTAB-8322	yes	1908.51
E-MTAB-9906	yes	1646.96
E-GEOD-150728	yes	1482.05

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

66 targeting COTL1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-3689D	100.00	66.14	1181
HSA-MIR-6851-5P	100.00	65.63	1294
HSA-MIR-3120-5P	100.00	65.56	965
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-1229-3P	99.97	66.49	906
HSA-MIR-3910	99.95	71.13	2227
HSA-MIR-101-3P	99.94	75.03	2230
HSA-MIR-144-3P	99.94	73.98	2698
HSA-MIR-6768-5P	99.92	67.36	1942
HSA-MIR-3686	99.90	70.53	2432
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-124-3P	99.89	73.74	3043
HSA-MIR-506-3P	99.89	73.55	3057
HSA-MIR-345-3P	99.89	70.23	1421
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-4698	99.84	71.41	4303
HSA-MIR-6756-5P	99.82	67.97	2466
HSA-MIR-7856-5P	99.75	69.99	2901
HSA-MIR-3714	99.71	70.74	2671
HSA-MIR-3175	99.65	66.30	2031
HSA-MIR-4690-5P	99.65	66.24	813
HSA-MIR-4743-3P	99.62	68.12	2095
HSA-MIR-762	99.58	66.61	1994

Literature-anchored findings (GeneRIF, showing 15)

• CLP 57-65 peptide elicits immediate-type hypersensitivity. Identical peptides are recognized by cellular and humoral immune systems to a tumor-associated antigen. CLP 15-24 and 104-113 might be used for peptide-based immunotherapy of HLA-A2(+) cancers. (PMID:11870627)
• NMR resonance assignments and the secondary structures of human Coactosin like protein (hCLP) D123N (PMID:15213466)
• coactosin-like protein (CLP) is an actin-binding protein as well as a 5-lipoxygenase binding partner (PMID:15333945)
• structural analysis shows that CLP forms a polymer along the crystallographic b axis with the exact same repeat distance as F-actin; a model for the CLP polymer and F-actin binding has therefore been proposed. (PMID:15459340)
• preliminary crystallographic studies of human coactosin-like protein (CLP) (PMID:15583396)
• Coactosin-like protein (CLP) up-regulates Ca(2+)-induced 5-lipoxygenase (5LO) activity, and increases the amount of Leukotriene A(4) formed by 5LO. (PMID:16924104)
• extended region of beta4-beta5 of hCLP (residue 66-75) was found very flexible and very important for F-actin binding. The C-terminal residues of human coactosin-like protein were not involved in F-actin binding (PMID:17070122)
• We found that coactosin-like1 (COTL1) were highly expressed in rheumatoid arthritis patients compared with healthy controls (PMID:19307756)
• Results of the present study support a role for CLP as a chaperoning scaffold factor, influencing both the stability and the activity of 5-LO. (PMID:19807693)
• Up-regulated COTL-1 expression in small cell lung cancer was validated by Western blot analysis, immunohistochemistry, and qRT-qPCR. (PMID:21047053)
• PAI-RBP1 and C1orf142 expression levels are higher in 95D (high metastatic potential) than in 95C (low metastatic potential) non-small lung cancer cells, whereas COTL1 expression level is lower in 95D when compared to 95C cells. (PMID:22373659)
• COTL1 regulates lamellipodia dynamics in part by protecting F-actin from cofilin-mediated disassembly. (PMID:24454796)
• The roles of CLP and FLAP in in cellular leukotriene biosynthesis, were studied. (PMID:25034252)
• our combined results elucidated genetic and epigenetic silencing of miR-506-3p enhances COTL1 oncogene expression to foster NSCLC progression. (PMID:27893417)
• Study uncovers a novel tumor-suppressor role for CLP/Cotl1 and identify the downstream effectors interleukin 24 (IL-24)/PERP and IL-24/MAPK/ERK/TGF-beta. (PMID:28925397)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	cotl1	ENSDARG00000026829
mus_musculus	Cotl1	ENSMUSG00000031827
rattus_norvegicus	Cotl1	ENSRNOG00000016257
drosophila_melanogaster	CG6891	FBGN0030955

Paralogs (4): CTTN (ENSG00000085733), DBN1 (ENSG00000113758), DBNL (ENSG00000136279), HCLS1 (ENSG00000180353)

Protein

Protein identifiers

Coactosin-like protein — Q14019 (reviewed: Q14019)

All UniProt accessions (4): Q14019, A0A087WWC7, A0A384MTY2, H3BT58

UniProt curated annotations — full annotation on UniProt →

Function. Binds to F-actin in a calcium-independent manner. Has no direct effect on actin depolymerization. Acts as a chaperone for ALOX5 (5LO), influencing both its stability and activity in leukotrienes synthesis.

Subunit / interactions. Interacts with 5-lipoxygenase (ALOX5/5LO) in a calcium-independent manner. Binds to F-actin with a stoichiometry of 1:2.

Subcellular location. Cytoplasm. Cytoskeleton. Nucleus.

Tissue specificity. Widely expressed with highest levels in placenta, lung, kidney and peripheral blood leukocytes and lower levels in brain, liver and pancreas.

Similarity. Belongs to the actin-binding proteins ADF family. Coactosin subfamily.

RefSeq proteins (1): NP_066972* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002108	ADF-H	Domain
IPR029006	ADF-H/Gelsolin-like_dom_sf	Homologous_superfamily

Pfam: PF00241

UniProt features (28 total): strand 8, helix 6, mutagenesis site 5, modified residue 3, initiator methionine 1, chain 1, sequence conflict 1, domain 1, turn 1, region of interest 1

Structure

Experimental structures (PDB)

6 structures.

PDB	Method	Resolution (Å)
1T3Y	X-RAY DIFFRACTION	1.15
1VFQ	X-RAY DIFFRACTION	1.9
1T3X	X-RAY DIFFRACTION	2
1T2L	X-RAY DIFFRACTION	2.8
1TMW	SOLUTION NMR
1WNJ	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q14019-F1	90.77	0.83

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (3): 2, 102, 126

Mutagenesis-validated functional residues (5):

Position	Phenotype
131	abolishes 5lo-binding activity.
131	no effect on 5lo-binding activity.
75	abolishes actin-binding activity.
130	no effect on 5lo-binding activity.

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-6798695	Neutrophil degranulation

MSigDB gene sets: 358 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_COLON_TUMORAL_MACROPHAGE_UP, GOBP_REGULATION_OF_PROTEIN_POLYMERIZATION, WALLACE_PROSTATE_CANCER_RACE_UP, REACTOME_INNATE_IMMUNE_SYSTEM, GOCC_SECRETORY_GRANULE, ZHAN_MULTIPLE_MYELOMA_MF_UP, STEARMAN_LUNG_CANCER_EARLY_VS_LATE_DN, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP, GAUSSMANN_MLL_AF4_FUSION_TARGETS_C_UP, MCBRYAN_PUBERTAL_TGFB1_TARGETS_UP, HUMMERICH_MALIGNANT_SKIN_TUMOR_UP, CACCAGC_MIR138, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, WIELAND_UP_BY_HBV_INFECTION

GO Biological Process (2): regulation of actin filament polymerization (GO:0030833), defense response to fungus (GO:0050832)

GO Molecular Function (4): actin binding (GO:0003779), enzyme binding (GO:0019899), actin filament binding (GO:0051015), protein binding (GO:0005515)

GO Cellular Component (11): extracellular region (GO:0005576), nucleus (GO:0005634), cytosol (GO:0005829), site of polarized growth (GO:0030427), cortical actin cytoskeleton (GO:0030864), secretory granule lumen (GO:0034774), extracellular exosome (GO:0070062), ficolin-1-rich granule lumen (GO:1904813), cytoplasm (GO:0005737), cytoskeleton (GO:0005856), actin filament (GO:0005884)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Innate Immune System	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
actin cytoskeleton	2
regulation of actin polymerization or depolymerization	1
actin filament polymerization	1
regulation of protein polymerization	1
defense response	1
response to fungus	1
cytoskeletal protein binding	1
protein binding	1
actin binding	1
protein-containing complex binding	1
binding	1
intracellular membrane-bounded organelle	1
cytoplasm	1
cortical cytoskeleton	1
secretory granule	1
cytoplasmic vesicle lumen	1
extracellular vesicle	1
intracellular organelle lumen	1
ficolin-1-rich granule	1
intracellular anatomical structure	1
intracellular membraneless organelle	1
polymeric cytoskeletal fiber	1

Protein interactions and networks

STRING

1194 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
COTL1	ALOX5	P09917	945
COTL1	ALOX5AP	P20292	787
COTL1	LTA4H	P09960	674
COTL1	LTC4S	Q16873	523
COTL1	CFL1	P23528	446
COTL1	POTEF	A5A3E0	434
COTL1	ACTB	P02570	424
COTL1	PFN1	P07737	415
COTL1	CCL3	P10147	403
COTL1	CXCL2	P19875	390
COTL1	CFL2	Q9Y281	389
COTL1	MMP2	P08253	388
COTL1	TUBB	P05218	386
COTL1	TCIRG1	Q13488	384
COTL1	AGT	P01019	382

IntAct

27 interactions, top by confidence:

A	B	Type	Score
COTL1	ALOX5	psi-mi:“MI:0407”(direct interaction)	0.700
ALOX5	COTL1	psi-mi:“MI:0915”(physical association)	0.700
COTL1	PDE6H	psi-mi:“MI:0915”(physical association)	0.560
PDE6H	COTL1	psi-mi:“MI:0915”(physical association)	0.560
COTL1	TERF2IP	psi-mi:“MI:0915”(physical association)	0.510
	COTL1	psi-mi:“MI:0407”(direct interaction)	0.440
COTL1	PPIB	psi-mi:“MI:0915”(physical association)	0.400
COTL1	CANX	psi-mi:“MI:0915”(physical association)	0.400
	TK2	psi-mi:“MI:0915”(physical association)	0.400
SH2D3C	ANXA2P2	psi-mi:“MI:0914”(association)	0.350
rep	GPR89A	psi-mi:“MI:0914”(association)	0.350
	SHTN1	psi-mi:“MI:0914”(association)	0.350
RHOG	COPE	psi-mi:“MI:0914”(association)	0.350
CACNA1C	SNRPGP15	psi-mi:“MI:0914”(association)	0.350
CFTR	UBA6	psi-mi:“MI:2364”(proximity)	0.270
MAPT	PITPNM1	psi-mi:“MI:2364”(proximity)	0.270
PINX1	COTL1	psi-mi:“MI:0915”(physical association)	0.000
VHL	COTL1	psi-mi:“MI:0915”(physical association)	0.000
PRKAB1	COTL1	psi-mi:“MI:0915”(physical association)	0.000
IKBKE	COTL1	psi-mi:“MI:0915”(physical association)	0.000
COTL1	TERF2IP	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (83): ALOX5 (Reconstituted Complex), COTL1 (Two-hybrid), ARHGDIA (Co-fractionation), CFL1 (Co-fractionation), COTL1 (Co-fractionation), COTL1 (Co-fractionation), COTL1 (Co-fractionation), CRIP1 (Co-fractionation), DUT (Co-fractionation), HN1 (Co-fractionation), MDH2 (Co-fractionation), PCBP1 (Co-fractionation), SH3BGRL (Co-fractionation), TAGLN2 (Co-fractionation), TIAL1 (Co-fractionation)

ESM2 similar proteins: A0PJN4, A1L167, A2VDL8, B0BNA5, F1LMZ8, O00231, O88544, O88761, O94973, P17427, P18484, P21566, P22234, P38024, P45591, P48444, P51583, P61201, P61202, P61203, P79101, P97834, Q01405, Q0VCK5, Q14019, Q148F1, Q15436, Q2HJ57, Q2KI42, Q2TBL9, Q3SZA0, Q3TXS7, Q5F418, Q5G6V9, Q5R5S4, Q5R9J9, Q5R9P3, Q5RA77, Q5RB59, Q6IQT4

Diamond homologs: B0BNA5, C4M4P4, P34121, Q14019, Q2HJ57, Q9CQI6, A6H7G2, Q62418, Q6GM14, Q7ZXQ9, Q9JHL4, Q9P7E8, Q9UJU6, Q9VU84

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

44 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	29
Likely benign	0
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

693 predictions. Top by Δscore:

Variant	Effect	Δscore
16:84566952:AATT:A	acceptor_gain	1.0000
16:84566953:ATT:A	acceptor_gain	1.0000
16:84566954:TT:T	acceptor_gain	1.0000
16:84566955:TCT:T	acceptor_loss	1.0000
16:84566956:C:CA	acceptor_loss	1.0000
16:84566956:C:CC	acceptor_gain	1.0000
16:84566957:T:G	acceptor_loss	1.0000
16:84590102:TACC:T	donor_loss	1.0000
16:84590103:A:T	donor_loss	1.0000
16:84590115:T:TA	donor_gain	1.0000
16:84590258:GTCAT:G	acceptor_gain	1.0000
16:84590259:TCAT:T	acceptor_gain	1.0000
16:84590260:CAT:C	acceptor_gain	1.0000
16:84590260:CATC:C	acceptor_gain	1.0000
16:84590261:AT:A	acceptor_gain	1.0000
16:84590262:TCTG:T	acceptor_loss	1.0000
16:84590263:C:CC	acceptor_gain	1.0000
16:84590264:T:A	acceptor_loss	1.0000
16:84590270:C:CT	acceptor_gain	1.0000
16:84590270:C:T	acceptor_gain	1.0000
16:84590271:A:T	acceptor_gain	1.0000
16:84590276:C:CT	acceptor_gain	1.0000
16:84590277:G:T	acceptor_gain	1.0000
16:84617583:CCTT:C	acceptor_gain	1.0000
16:84617591:T:C	acceptor_gain	1.0000
16:84617832:TCCTA:T	donor_loss	1.0000
16:84617833:CCTAC:C	donor_loss	1.0000
16:84617834:CTAC:C	donor_loss	1.0000
16:84617835:TA:T	donor_loss	1.0000
16:84617836:A:AC	donor_gain	1.0000

AlphaMissense

940 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
16:84566865:A:G	Y137H	1.000
16:84566873:C:T	G134E	1.000
16:84566888:A:G	L129P	1.000
16:84590148:G:T	A92D	1.000
16:84590182:A:G	W81R	1.000
16:84590182:A:T	W81R	1.000
16:84590195:A:C	F76L	1.000
16:84590195:A:T	F76L	1.000
16:84590197:A:G	F76L	1.000
16:84590198:C:A	K75N	1.000
16:84590198:C:G	K75N	1.000
16:84590200:T:C	K75E	1.000
16:84590204:C:A	R73S	1.000
16:84590204:C:G	R73S	1.000
16:84590205:C:A	R73M	1.000
16:84566864:T:C	Y137C	0.999
16:84566870:G:T	A135D	0.999
16:84566874:C:G	G134R	0.999
16:84566874:C:T	G134R	0.999
16:84566943:C:T	E111K	0.999
16:84566948:G:T	A109D	0.999
16:84590109:A:T	V105E	0.999
16:84590121:A:T	V101E	0.999
16:84590129:C:A	K98N	0.999
16:84590129:C:G	K98N	0.999
16:84590151:C:G	R91P	0.999
16:84590152:G:T	R91S	0.999
16:84590175:C:A	G83V	0.999
16:84590175:C:T	G83D	0.999
16:84590176:C:G	G83R	0.999

dbSNP variants (sampled 300 via entrez): RS1000003468 (16:84618697 C>T), RS1000049611 (16:84582515 C>A,T), RS1000107960 (16:84566073 G>C), RS1000108055 (16:84615831 C>T), RS1000177914 (16:84602991 G>A), RS1000188332 (16:84591026 T>C), RS1000273071 (16:84611970 C>T), RS1000303334 (16:84566500 C>T), RS1000306109 (16:84591267 T>C), RS1000344734 (16:84578131 C>G,T), RS1000354768 (16:84618927 A>T), RS1000355292 (16:84582310 A>T), RS1000357461 (16:84595280 G>C), RS1000387783 (16:84582164 T>G), RS1000420430 (16:84566341 G>A)

Disease associations

OMIM: gene MIM:606748 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST002949_20	Epilepsy and lamotrigine-induced maculopapular eruptions	9.000000e-07
GCST005652_8	Cleft lip with or without cleft palate (maternal periconceptional vitamin use interaction)	6.000000e-06
GCST006976_101	Macular thickness	2.000000e-13
GCST006979_635	Heel bone mineral density	5.000000e-09
GCST008399_6	Cocaine dependence	9.000000e-06
GCST010151_24	Carotid intima media thickness x smoking interaction	5.000000e-06

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:1001253	maculopapular eruption
EFO:0003959	cleft lip
EFO:0009116	vitamin supplement exposure measurement
EFO:0009270	heel bone mineral density
EFO:0006527	smoking status measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

72 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
methylmercuric chloride	increases expression, affects cotreatment	4
bisphenol A	decreases expression, increases expression, affects cotreatment	4
Valproic Acid	affects expression, increases expression	4
Benzo(a)pyrene	decreases expression, affects methylation	3
Cyclosporine	decreases expression	3
sodium arsenite	decreases expression, increases expression	2
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	increases expression, affects cotreatment	2
Doxorubicin	affects expression, decreases expression	2
Phenylmercuric Acetate	increases expression, affects cotreatment	2
Smoke	decreases expression, increases expression	2
Tetrachlorodibenzodioxin	decreases expression	2
Tobacco Smoke Pollution	affects expression, increases expression	2
Tretinoin	affects cotreatment, increases expression	2
Aflatoxin B1	increases expression	2
Cadmium Chloride	increases abundance, increases expression	2
aristolochic acid I	increases expression	1
beauvericin	decreases expression	1
triphenyl phosphate	affects expression	1
propionaldehyde	increases expression	1
pirinixic acid	affects binding, increases activity, increases expression	1
glycidyl methacrylate	increases expression	1
pyrogallol 1,3-dimethyl ether	decreases expression, affects cotreatment	1
trichostatin A	affects expression	1
tris(2-butoxyethyl) phosphate	affects expression	1
arsenite	affects binding, increases reaction	1
cobaltous chloride	decreases expression	1
butyraldehyde	increases expression	1
potassium chromate(VI)	affects cotreatment, increases expression	1
aflatoxin B2	decreases methylation	1
isobutyl alcohol	affects cotreatment, increases abundance, increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.